Drugs / ChulaCov19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04566276 | May 2021 → Oct 2022 | — | Chulalongkorn University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChulaCov19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04566276 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine” NCT04566276 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT04566276 ↗ |